Pfizer Japan Inc. (Tokyo, “Pfizer”) and Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) today announced that the companies have agreed to terminate the distribution and co-promotion agreement in Japan for a combination drug of hypertension treatment and hypercholesterolemia treatment Caduet® Combination Tablets (generic name: amlodipine besylate and atorvastatin calcium) on March 31, 2015.
In accordance with this agreement, Caduet® promotion, which to date has been carried out jointly by both companies, will be conducted solely by Pfizer from October 1, 2014. Astellas will continue its distribution until the termination of the agreement, and the distribution will be transferred to Pfizer on April 1, 2015.
Pfizer and Astellas will continue to co-promote hypercholesterolemia and familial hypercholesterolemia treatment Lipitor® Tablets (generic name: atorvastatin calcium) as in the past.
Caduet® Combination Tablets is an oral combination drug of hypertension treatment Norbasc® Tablets (generic name: amlodipine besylate) sold by Pfizer, and Lipitor® Tablets co-promoted by Pfizer and Astellas. In August 2009, Pfizer and Astellas concluded a co-promotion agreement for Caduet® Combination Tablets and have been conducting co-promotion activity since the product’s launch in December of the same year.